Literature DB >> 30179315

The Irwin Test and Functional Observational Battery (FOB) for Assessing the Effects of Compounds on Behavior, Physiology, and Safety Pharmacology in Rodents.

Joanne R Mathiasen1, Virginia C Moser2.   

Abstract

The modified Irwin procedure or functional observational battery (FOB) can be used to achieve several goals. New chemical entities (NCEs) can be behaviorally screened for nervous system effects at a variety of doses to identify potential therapeutic uses and in the selection of appropriate doses for subsequent assays. NCEs can also be evaluated in the behavioral battery and compared with reference standards to assess liabilities in a new compound class, with an estimated therapeutic index being suggested by the doses used in comparison to therapeutic doses. For the assessment of neurotoxicology, the FOB is often used. The differences between the two assays are subtle. The procedures used are essentially the same, but when considering neurotoxicology, the FOB is often conducted using GLP guidelines, with more animals being used per group, and doses that are low enough to determine a no effect level and high enough to induce marked nervous system behaviors.
© 2018 by John Wiley & Sons, Inc. © 2018 John Wiley & Sons, Inc.

Keywords:  FOB; Irwin; behavior; neurotoxicology; risk assessment; rodent; safety

Mesh:

Year:  2018        PMID: 30179315     DOI: 10.1002/cpph.43

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  9 in total

1.  The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.

Authors:  Kathryn M Lemberg; Liang Zhao; Ying Wu; Vijayabhaskar Veeravalli; Jesse Alt; Joanna Marie H Aguilar; Ranjeet P Dash; Jenny Lam; Lukáš Tenora; Chabely Rodriguez; Michael T Nedelcovych; Cory Brayton; Pavel Majer; Jaishri O Blakeley; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

2.  Biochemical, hematological and histopathological evaluation of the toxicity potential of the leaf extract of Stachytarpheta cayennensis in rats.

Authors:  Oladotun A Olayode; Michael Oluwatoyin Daniyan; Gbola Olayiwola
Journal:  J Tradit Complement Med       Date:  2019-05-16

Review 3.  Probing the Neural Circuitry Targets of Neurotoxicants In Vivo Through High Density Silicon Probe Brain Implants.

Authors:  Marcia H Ratner; David H Farb
Journal:  Front Toxicol       Date:  2022-04-25

4.  Evaluation in a Cytokine Storm Model In Vivo of the Safety and Efficacy of Intravenous Administration of PRS CK STORM (Standardized Conditioned Medium Obtained by Coculture of Monocytes and Mesenchymal Stromal Cells).

Authors:  Juan Pedro Lapuente; Gonzalo Gómez; Joaquín Marco-Brualla; Pablo Fernández; Paula Desportes; Jara Sanz; Mario García-Gil; Fernando Bermejo; Juan Víctor San Martín; Alicia Algaba; Juan Carlos De Gregorio; Daniel Lapuente; Almudena De Gregorio; Belén Lapuente; Sergio Gómez; María de Las Viñas Andrés; Alberto Anel
Journal:  Biomedicines       Date:  2022-05-08

5.  Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque.

Authors:  Xuedong Dai; Weijun Zhao; Xin Tong; Wei Liu; Xianhuan Zeng; Xiaohui Duan; Hua Wu; Lili Wang; Zhen Huang; Xinying Tang; Yong Yang
Journal:  Arch Toxicol       Date:  2022-02-28       Impact factor: 6.168

6.  Profiling Secreted miRNA Biomarkers of Chemical-Induced Neurodegeneration in Human iPSC-Derived Neurons.

Authors:  Dahea You; Jennifer D Cohen; Olga Pustovalova; Lauren Lewis; Lei Shen
Journal:  Toxicol Sci       Date:  2022-03-28       Impact factor: 4.849

7.  Mutagenicity and safety pharmacology of a standardized antidiabetic polyherbal formulation.

Authors:  Fadzilah Adibah Abdul Majid; Anis Fadhlina; Hassan Fahmi Ismail; Siti Nurazwa Zainol; Archan Kumar Mamillapalli; Vijayabalaji Venkatesan; Rajesh Eswarappa; Renuka Pillai
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.996

Review 8.  The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.

Authors:  Karen S Wilcox; Peter J West; Cameron S Metcalf
Journal:  Neuropharmacology       Date:  2019-11-30       Impact factor: 5.273

9.  Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.

Authors:  Carlos Chaccour; Gloria Abizanda; Ángel Irigoyen-Barrio; Aina Casellas; Azucena Aldaz; Fernando Martínez-Galán; Felix Hammann; Ana Gloria Gil
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.